Johnson & Johnson quarterly sales rise

Share this article:

Johnson and Johnson's second-quarter spreadsheet showed sales jumped 8.5% to $17.8 billion for the quarter, compared to $16.4 for the same period last year. Sales for the first six months of the year were also up 8.5%, hitting $35.3 billion, compared to $32.6 for the same period the year before. The uptick translated into a jump in profits—$3.8 billion for the quarter, and $7.3 billion for the six-month period—but as noted by Forbes, these numbers lose some of their heft due to “a brutal 2012” benchmark. Selling its share in Elan helped bolster the company's results.

Quarter standouts included an 8% bump in US consumer sales to $7.9 billion, compared to $7.3 billion for the same period last year. Numbers for the six-month mark were $15.9 billion in US sales compared to $14.5 billion and $35.3 billion in worldwide sales compared to $32.6 billion for the same period last year.

Over-the-counter sales rebounded, rising 5.4% worldwide to $931 million for the quarter, compared to $883 million for the same period last year. The company's pharmaceutical lineup included a 4% bump in Remicade sales to $926 million, compared to $890 million for the quarter ($1.6 billion worldwide compared to $1.5 billion), while Simponi sales rose 38% to $87 million for the quarter compared to $63 million ($175 million worldwide compared to $125 million) and Stelara sales jumped over 53% in the US to $233 million compared to $152 million ($371 million worldwide compared to $248 million).

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...